Abstract
The purpose of this study was to assess the pharmacokinetic profile of ciprofloxacin in 12 patients with diabetic gastroparesis. Patients received both a single 500-mg oral (p.o.) dose and a single 400-mg intravenous (i.v.) dose of ciprofloxacin separated by a 1-week washout period. Pharmacokinetic parameters (means +/- standard deviations) for the p.o. and i.v. doses were as follows: areas under the concentration-time curve from 0 h to infinity, 9.74 +/- 2.59 and 11.78 +/- 3.18 micrograms.h/ml, respectively; maximum concentrations of drug in serum, 2.13 +/- 0.67 and 4.21 +/- 1.07 micrograms/ml, respectively; and half-lives, 4.03 +/- 0.58 and 4.20 +/- 0.58 h, respectively. The ratio of the areas under the concentration-time curves from 0 h to infinity for the p.o. and i.v. doses was 0.84, with a 90% confidence interval of 0.68 to 0.98; the mean absolute bioavailability was calculated to be 67% (range, 43 to 82%). From these data it appears that ciprofloxacin is adequately absorbed in patients with diabetic gastroparesis.
Full Text
The Full Text of this article is available as a PDF (165.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Bergan T., Dalhoff A., Rohwedder R. Pharmacokinetics of ciprofloxacin. Infection. 1988;16 (Suppl 1):S3–13. doi: 10.1007/BF01650500. [DOI] [PubMed] [Google Scholar]
- Feldman M., Corbett D. B., Ramsey E. J., Walsh J. H., Richardson C. T. Abnormal gastric function in longstanding, insulin-dependent diabetic patients. Gastroenterology. 1979 Jul;77(1):12–17. [PubMed] [Google Scholar]
- Feldman M., Schiller L. R. Disorders of gastrointestinal motility associated with diabetes mellitus. Ann Intern Med. 1983 Mar;98(3):378–384. doi: 10.7326/0003-4819-98-3-378. [DOI] [PubMed] [Google Scholar]
- Gasser T. C., Ebert S. C., Graversen P. H., Madsen P. O. Ciprofloxacin pharmacokinetics in patients with normal and impaired renal function. Antimicrob Agents Chemother. 1987 May;31(5):709–712. doi: 10.1128/aac.31.5.709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Greenblatt D. J., Kock-Weser J. Drug therapy. Clinical Pharmacokinetics (first of two parts). N Engl J Med. 1975 Oct 2;293(14):702–705. doi: 10.1056/NEJM197510022931406. [DOI] [PubMed] [Google Scholar]
- Lettieri J. T., Rogge M. C., Kaiser L., Echols R. M., Heller A. H. Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses. Antimicrob Agents Chemother. 1992 May;36(5):993–996. doi: 10.1128/aac.36.5.993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rothstein R. D. Gastrointestinal motility disorders in diabetes mellitus. Am J Gastroenterol. 1990 Jul;85(7):782–785. [PubMed] [Google Scholar]
- Schuirmann D. J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987 Dec;15(6):657–680. doi: 10.1007/BF01068419. [DOI] [PubMed] [Google Scholar]
- Vance-Bryan K., Guay D. R., Rotschafer J. C. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet. 1990 Dec;19(6):434–461. doi: 10.2165/00003088-199019060-00003. [DOI] [PubMed] [Google Scholar]